Literature DB >> 7411387

Determination of haloperidol in human serum by radioimmunoassay.

H Suzuki, Y Minaki, M Iwaisaki, Y Sekine, A Kagemoto, Y Utsui, M Hashimoto, G Yagi, H Itoh.   

Abstract

A radioimmunoassay has been developed which enables accurate determination of haloperidol in human serum. Antiserum was prepared by immunizing guinea pigs with haloperidol (O-carboxymethyl)oxime derivative (III) coupled with bovine serum albumin. With the antiserum, 3H-haloperidol and dextran-coated charcoal, the assay of haloperidol in serum was possible over a concentration range of 1 to 50 ng/ml, using 0.1 ml of human serum without the need of an extraction procedure. Data obtained by radioimmunoassay are in good agreement with those obtained by gas chromatography. No appreciable cross-reactivity was observed neither with haloperidol metabolites nor with other butyrophenone neuroleptics. Serum levels of haloperidol in schizophrenic patients receiving single oral dosing (6 mg/subject) have also been determined.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7411387     DOI: 10.1248/bpb1978.3.250

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  4 in total

1.  Human scalp hair as evidence of individual dosage history of haloperidol: method and retrospective study.

Authors:  T Uematsu; R Sato; K Suzuki; S Yamaguchi; M Nakashima
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Human scalp hair as evidence of individual dosage history of haloperidol: a possible linkage of haloperidol excretion into hair with hair pigment.

Authors:  T Uematsu; R Sato; O Fujimori; M Nakashima
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  The measurement of haloperidol and reduced haloperidol in hair as an index of dosage history.

Authors:  H Matsuno; T Uematsu; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

Review 4.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.